Online first
Letter to the Editors
Published online: 2024-07-09

open access

Page views 155
Article views/downloads 134
Get Citation

Connect on Social Media

Connect on Social Media

Switching from oral ropinirole to ropinirole transdermal patch in patients with Parkinson’s Disease: an observational study

Yuki Yasutaka12, Takayasu Mishima3, Shinsuke Fujioka3, Kentaro Ogata12, Hidetoshi Kamimura12, Yoshio Tsuboi3

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. Parkinsonism Relat Disord. 2009; 15 Suppl 4: S97–100.
  2. Mochizuki H, Hattori N, Hasegawa K, et al. Long-term study of ropinirole patch in Parkinson's disease patients with/without basal l-dopa. Parkinsonism Relat Disord. 2021; 83: 105–109.
  3. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010; 25(15): 2649–2653.
  4. Schade S, Mollenhauer B, Trenkwalder C. Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide. Mov Disord Clin Pract. 2020; 7(3): 343–345.